1.Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis.
Suman S KARANTH ; Anurag GUPTA ; Mukhyaprana PRABHU
Singapore medical journal 2014;55(1):e7-8
Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis. We report the case of a 50-year-old woman who was incidentally detected to have essential thrombocytosis after suffering an episode of cerebrovascular accident with faciobrachial monoparesis. She was subsequently initiated on hydroxyurea. Within seven weeks of therapy, the patient noticed irregular hyperpigmented patches over her feet, hands and perioral region, with bluish-grey longitudinal bands on all 20 nails. Hydroxyurea-induced hyperpigmentation and melanonychia are not commonly reported. To the best of our knowledge, this is only the third published report of hydroxyurea-induced hyperpigmentation and melanonychia involving all 20 nails. Physicians need to be aware of such mucocutaneous side effects to avoid misdiagnosis and unwarranted fear in patients. The decision to discontinue the intake of the drug depends heavily on the future risk of thrombotic events.
Female
;
Humans
;
Hydroxyurea
;
adverse effects
;
therapeutic use
;
Hyperpigmentation
;
chemically induced
;
Middle Aged
;
Nail Diseases
;
chemically induced
;
Nails
;
drug effects
;
Stroke
;
drug therapy
;
Thrombocytosis
;
drug therapy
;
Treatment Outcome
2.Nail Changes During Docetaxel Containing Combination Chemotherapy.
In Sook WOO ; Kon Ho SHIM ; Gi Young KIM ; Myung Ah LEE ; Jin Hyoung KANG ; Young Seon HONG ; Kyung Shik LEE
The Korean Journal of Internal Medicine 2004;19(2):132-133
Nail toxicity following systemic chemotherapy is common. Onychopathy during the period of neutropenia following chemotherapy may cause subungual abscesses and serious infection. Despite taxoid-related toxicity being increasingly reported since 2000, there are still phase II systemic chemotherapy studies using taxoid that have never mentioned nail changes. Recently, new criteria for the evaluation of nail toxicity have been suggested. The present report is the first of its kind, in Korea, to describe a case of docetaxel-associated onychopathy, which improved following a reduction in the docetaxel dose.
Antimetabolites, Antineoplastic/administration & dosage
;
Antineoplastic Agents, Phytogenic/administration & dosage/adverse effects
;
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
;
Deoxycytidine/administration & dosage/analogs & derivatives
;
Dose-Response Relationship, Drug
;
Female
;
Fluorouracil/analogs & derivatives
;
Humans
;
Lymphatic Diseases/drug therapy
;
Middle Aged
;
Nail Diseases/*chemically induced
;
Stomach Neoplasms/drug therapy
;
Taxoids/*administration & dosage/*adverse effects